Author: admin

Cutaneous T-Cell Lymphoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)

DelveInsight’s, “Cutaneous T-Cell Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 30+ Cutaneous T-Cell Lymphoma Companies and 35+ pipeline drugs in the Cutaneous T-Cell Lymphoma pipeline landscape. It covers the Cutaneous T-cell lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cutaneous T-cell lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Cutaneous T-cell Lymphoma Pipeline Report

  • DelveInsight’s Cutaneous T-cell lymphoma pipeline report depicts a robust space with 30+ active players working to develop 35+ pipeline therapies for Cutaneous T-cell lymphoma treatment.
  • The leading companies working in the Cutaneous T-cell lymphoma Market include Medivir, 4SC, Myeloid Therapeutics, Mundipharma International, Shanghai Pharmaceuticals Holding, Soligenix, Affimed GmbH, Merck & Co., Inc., Philogen S.p.A., Innate Pharma, Hoffman-La-Roche, Galderma, Vidac Pharma, BeiGene, Otsuka Pharmaceutical, and others.
  • Promising Cutaneous T-Cell Lymphoma Pipeline Therapies in the various stages of development include romidepsin (depsipeptide, FK228), Brentuximab Vedotin, Methotrexate, Bexarotene, and others.
  • December 2023: University College, London announced a study of Phase 2 clinical trials for Pembrolizumab. Trial Subjects (patients), will receive single infusions of pembrolizumab every 3 weeks until disease progression or unacceptable toxicity develops. They will receive radiotherapy at week 12.
  • December 2023: Soligenix announced a study of Phase 2 clinical trials for Hypericin and Mechlorethamine Topical Gel. The objective of this clinical study is to compare the safety and effectiveness of Valchlor versus HyBryte following 12 weeks of treatment.
  • September 2023: Takeda announced a study of Phase 4 clinical trials for Brentuximab vedotin. The main aim is to check the long-term side effects of treatment with Brentuximab Vedotin and to see if that treatment improves symptoms of cluster of differentiation antigen 30 (CD30-Positive) Cutaneous T-Cell Lymphoma in Chinese adults. Participants will receive brentuximab vedotin through the vein on day 1 of each 21 day cycle up to maximum 16 cycles.
  • September 2023: Jiangsu Simcere Biologics Co. Ltd announced a study of Phase 1 clinical trials for SIM 1811-03 or in combination with Sintilimab injectiont. This is a first in human, open-label, dose escalation and expansion Phase I study of SIM1811-03 in adult patients with advanced tumors. SIM1811-03 is a first-in-class IgG1-based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors.

 

Request a sample and discover the recent advances in Cutaneous T-cell lymphoma Treatment Drugs @ Cutaneous T-cell lymphoma Pipeline Outlook Report

 

In the Cutaneous T-cell lymphoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cutaneous T-Cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Cutaneous T-cell lymphoma Overview

Malignant lymphomas can present in the skin either as a primary or secondary manifestation of the disease. The term primary cutaneous lymphoma (PCL) refers to a heterogeneous group of cutaneous T-cell lymphomas (CTCLs) and cutaneous B-cell lymphomas (CBCLs).

 

Find out more about Cutaneous T-cell lymphoma Therapeutics Assessment @ Cutaneous T-cell lymphoma Preclinical and Discovery Stage Products

 

Cutaneous T-cell lymphoma Emerging Drugs Profile

  • SHP-141: Medivir
  • Resminostat: 4SC
  • MT-101: Myeloid Therapeutics
  • Tinostamustine: Mundipharma International
  • B006: Shanghai Pharmaceuticals Holding

 

Cutaneous T-Cell Lymphoma Pipeline Therapeutics Assessment

There are approx. 30+ key Cutaneous T-Cell Lymphoma companies which are developing the Cutaneous T-Cell Lymphoma therapies. The Cutaneous T-Cell Lymphoma companies which have their Cutaneous T-Cell Lymphoma drug candidates in the most advanced stage, i.e. phase II include, Medivir.

 

DelveInsight’s Cutaneous T-Cell Lymphoma pipeline report covers around 35+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Cutaneous T-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Cutaneous T-cell lymphoma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Learn more about the emerging Cutaneous T-cell lymphoma Pipeline Therapies @ Cutaneous T-Cell Lymphoma Clinical Trials Assessment

 

Scope of the Cutaneous T-cell lymphoma Pipeline Report

  • Coverage- Global
  • Cutaneous T-cell lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Cutaneous T-cell lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Cutaneous T-cell lymphoma Companies– Medivir, 4SC, Myeloid Therapeutics, Mundipharma International, Shanghai Pharmaceuticals Holding, Soligenix, Affimed GmbH, Merck & Co., Inc., Philogen S.p.A., Innate Pharma, Hoffman-La-Roche, Galderma, Vidac Pharma, BeiGene, Otsuka Pharmaceutical, and others.
  • Cutaneous T-Cell Lymphoma Pipeline Therapies–Romidepsin (depsipeptide, FK228), Brentuximab Vedotin, Methotrexate, Bexarotene, and others.

 

Dive deep into rich insights for new drugs for Cutaneous T-cell lymphoma Treatment, Visit @ Cutaneous T-cell lymphoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Cutaneous T-Cell Lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Cutaneous T-Cell Lymphoma– DelveInsight’s Analytical Perspective
  7. Mid Stage Products (Preregistration)
  8. Drug Name: Company Name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. SHP-141: Medivir
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Tinostamustine: Mundipharma International
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Cutaneous T-Cell Lymphoma Key Companies
  21. Cutaneous T-Cell Lymphoma Key Products
  22. Cutaneous T-Cell Lymphoma- Unmet Needs
  23. Cutaneous T-Cell Lymphoma- Market Drivers and Barriers
  24. Cutaneous T-Cell Lymphoma- Future Perspectives and Conclusion
  25. Cutaneous T-Cell Lymphoma Analyst Views
  26. Cutaneous T-Cell Lymphoma Key Companies
  27. Appendix

 

For further information on the Cutaneous T-cell lymphoma Pipeline therapeutics, reach out to Cutaneous T-cell lymphoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-melanoma-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cutaneous T-Cell Lymphoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)

CRISPR Therapies Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)

DelveInsight’s, “CRISPR Therapies Pipeline Insight 2023” report provides comprehensive insights about 25+ CRISPR Therapies Companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CRISPR Therapies therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive CRISPR Therapies pipeline products in this space.

 

Key Takeaways from the CRISPR Therapies Pipeline Report

  • DelveInsight’s CRISPR Therapies pipeline report depicts a robust space with 25+ CRISPR Therapies companies working to develop 25+ pipeline therapies for CRISPR Therapies treatment.
  • The leading CRISPR Therapies Companies working in the market include Intellia Therapeutics, CRISPR therapeutics, Repare Therapeutics, Beam therapeutics, Caribou Biosciences, Emendo Biotherapeutics, Defence Therapeutics, Sarepta therapeutics, Editas Medicine, Locus Biosciences, Excision BioTherapeutics, AstraZeneca, Novartis, ASC therapeutics, Casebia therapeutics, Spotlight Therapeutics, KSQ Therapeutics, MEDIC Life Sciences, Scribe therapeutics, Arbor Biotechnologies, Sangamo therapeutics, Graphite Bio, Nuntius Therapeutics, and others.
  • Promising CRISPR Therapies in the various stages of development include BD111 Adult single group Dose, HG202, CB-011, Cyclophosphamide, Fludarabine, Aldesleukin, EBT-101, and others.
  • November 2023: HuidaGene Therapeutics Co. Ltd. announced a study of early phase 1 clinical trials for HG202. A Trial to Evaluate the Safety, Tolerability, and Efficacy of CRISPR-Cas13 RNA-editing Therapy Targeting Knockdown of Vascular Endothelial Growth Factor A (HG202) in the Treatment of Neovascular Age-related Macular Degeneration (nAMD).
  • November 2023: Caribou Biosciences Inc. announced a study of Phase 1 clinical trials for CB-011. This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).

 

Request a sample and discover the recent advances in CRISPR Therapies Treatment Drugs @ CRISPR Therapies Pipeline Outlook Report

 

The CRISPR Therapies pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage CRISPR Therapies drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the CRISPR Therapies clinical trial landscape.

 

CRISPR Therapies Overview

CRISPRs are specialized stretches of DNA. “”CRISPR”” stands for “”clusters of regularly interspaced short palindromic repeats.”” It is a specialized region of DNA with two distinct characteristics: the presence of nucleotide repeats and spacers. Repeated sequences of nucleotides — the building blocks of DNA — are distributed throughout a CRISPR region.

 

Find out more about CRISPR Therapies Treatment Landscape @ Drugs for CRISPR Therapies Treatment

 

CRISPR Therapies Emerging Drugs Profile

  • CTX001: CRISPR Therapeutics
  • EDIT-101: Editas Medicine

 

CRISPR Therapies Pipeline Therapeutics Assessment

There are approx. 25+ key CRISPR Therapies companies which are developing the CRISPR Therapies. The CRISPR Therapies companies which have their CRISPR Therapies drug candidates in the most advanced stage, i.e. Phase I/II include, CRISPR therapeutics.

 

DelveInsight’s CRISPR Therapies Pipeline Report covers around 30+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

CRISPR Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

 

CRISPR Therapies Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Learn more about the emerging CRISPR Therapies Pipeline Therapies @ CRISPR Therapies Clinical Trials Assessment

 

Scope of the CRISPR Therapies Pipeline Report

  • Coverage- Global
  • CRISPR Therapies Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • CRISPR Therapies Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • CRISPR Therapies Companies- Intellia Therapeutics, CRISPR therapeutics, Repare Therapeutics, Beam therapeutics, Caribou Biosciences, Emendo Biotherapeutics, Defence Therapeutics, Sarepta therapeutics, Editas Medicine, Locus Biosciences, Excision BioTherapeutics, AstraZeneca, Novartis, ASC therapeutics, Casebia therapeutics, Spotlight Therapeutics, KSQ Therapeutics, MEDIC Life Sciences, Scribe therapeutics, Arbor Biotechnologies, Sangamo therapeutics, Graphite Bio, Nuntius Therapeutics, and others.
  • CRISPR Therapies- BD111 Adult single group Dose, HG202, CB-011, Cyclophosphamide, Fludarabine, Aldesleukin, EBT-101, and others.

 

Dive deep into rich insights for new drugs for CRISPR Therapies treatment, Visit @ CRISPR Therapies Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. CRISPR Therapies: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Drug Name: Company Name
  8. Drug profiles in the detailed report…..
  9. Early Stage Products (Phase I/II)
  10. CTX001: CRISPR Therapeutics
  11. Drug profiles in the detailed report…..
  12. Early stage products (Phase I)
  13. LBP-EC01: Locus Biosciences
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. CRISPR Therapies Key Companies
  17. CRISPR Therapies Key Products
  18. CRISPR Therapies- Unmet Needs
  19. CRISPR Therapies- Market Drivers and Barriers
  20. CRISPR Therapies- Future Perspectives and Conclusion
  21. CRISPR Therapies Analyst Views
  22. CRISPR Therapies Key Companies
  23. Appendix

 

For further information on the CRISPR Therapies pipeline therapeutics, reach out to CRISPR Therapies Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-melanoma-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CRISPR Therapies Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)

Janus kinase (JAK) Inhibitors Competitive Landscape Report 2023 (Updated) | Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, and Others.

DelveInsight’s, “Janus kinase inhibitors Competitive landscape 2023” report provides comprehensive insights about 40+ Janus kinase Inhibitors Companies and 45+ drugs in Janus kinase inhibitors Competitive landscape. It covers the Janus kinase Inhibitors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Janus kinase Inhibitors Report

  • DelveInsight’s Janus kinase Inhibitors report depicts a robust space with 40+ Janus kinase Inhibitors companies working to develop 45+ pipeline therapies for Janus kinase Inhibitors treatment.
  • The leading Janus kinase Inhibitors Companies working in the market include Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, and others.
  • Promising Janus kinase Inhibitors Therapies in the various stages of development include KPL-404, Baricitinib, Ruxolitinib, GSK3196165 (Otilimab), Sarilumab, csDMARDs, AZD4205, TD-0903, TL-895, and others.
  • December 2023: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announced a study of Phase 2 clinical trials for Abrocitinib 200 MG Oral Tablet and Ritlecitinib. A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
  • December 2023: Celgene announced a study of Phase 3 clinical trials for ACE-536. The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions.

 

Request a sample and discover the recent advances in Janus kinase Inhibitors Drugs @ Janus kinase Inhibitors Competitive Landscape Report

 

The Janus kinase Inhibitors report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the Janus kinase Inhibitors report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

 

Janus kinase Inhibitors Overview

Janus kinase (JAK) inhibitors are small molecules approximately 400 Da that could be administrated as oral medicines. JAKs are phosphotransferases that bind to the intracellular domains of cytokine receptors and transmit signals to activate immune responses. The family of cytokines that signal via JAKs includes many interleukins, interferons, colony stimulating factors and hormone like cytokines (such as erythropoietin).

 

Find out more about Janus kinase Inhibitors Analytical Perspective: In-depth Commercial Assessment @ Janus kinase Inhibitors Collaboration Analysis by Companies

 

Janus kinase Inhibitors Companies and Therapies

  • Eli Lilly and Company: OLUMIANT
  • AbbVie: RINVOQ
  • Galapagos: Filgotinib
  • Incyte: Povorcitinib
  • MaxiNovel Pharmaceuticals: MAX-40279/MAX-40070

 

Janus kinase Inhibitors Competitive Landscape: Analytical Perspective

The Janus kinase Inhibitors report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

 

JAK Inhibitors Report Assessment

  • Janus kinase Inhibitors Company Analysis
  • Janus kinase Inhibitors Therapeutic Assessment
  • Janus kinase Inhibitors Pipeline Assessment
  • Inactive drugs assessment
  • Janus kinase Inhibitors Unmet Needs

 

Learn more about the emerging Janus kinase Inhibitors Competitive Landscape @ Janus kinase Inhibitors Market Drivers and Barriers, Unmet Needs

 

Scope of the Janus kinase Inhibitors Report

  • Coverage- Global
  • Janus kinase Inhibitors Companies- Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, and others.
  • Janus kinase Inhibitors Therapies- KPL-404, Baricitinib, Ruxolitinib, GSK3196165 (Otilimab), Sarilumab, csDMARDs, AZD4205, TD-0903, TL-895, and others.
  • Janus kinase Inhibitors Therapeutics Assessment- Product Type, Stage and Product Type, Route of Administration, Stage and Route of Administration, Molecule Type, Stage and Molecule Type

 

Dive deep into rich insights for new drugs for Janus kinase Inhibitors Product Developmental Activities, Visit @ Janus kinase Inhibitors Research and Development Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. JAK inhibitors: Overview
  4. JAK inhibitors -Analytical Perspective: In-depth Commercial Assessment
  5. Competitive Landscape
  6. Therapeutic Assessment
  7. JAK inhibitors: Company and Product Profiles (Marketed Therapies)
  8. Eli Lilly and Company
  9. OLUMIANT
  10. JAK inhibitors: Company and Product Profiles (Pipeline Therapies)
  11. Late Stage Products (Phase III)
  12. Galapagos
  13. Filgotinib
  14. Drug profiles in the detailed report…..
  15. Mid Stage Products (Phase II)
  16. MaxiNovel Pharmaceuticals
  17. MAX-40279
  18. Drug profiles in the detailed report…..
  19. Early Stage Products (Phase I)
  20. MaxiNovel Pharmaceuticals
  21. MAX-40070
  22. Drug profiles in the detailed report…..
  23. Preclinical and Discovery Stage Products
  24. Company Name
  25. Product Name
  26. Drug profiles in the detailed report…..
  27. Inactive Products
  28. JAK inhibitors- Unmet needs
  29. JAK inhibitors – Market drivers and barriers
  30. Appendix

 

For further information on the Janus kinase Inhibitors Report @ Janus kinase Inhibitors Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-melanoma-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Janus kinase (JAK) Inhibitors Competitive Landscape Report 2023 (Updated) | Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, and Others.

Better Butts Launches New Bidet for Fresher, More Sustainable Bathrooms

The Better Butts bidet provides an affordable, easy-to-install solution for better hygiene and less toilet paper waste.

Tampa, FL startup Better Butts has launched a new non-electric bidet that makes bathrooms fresher and more sustainable without breaking the bank. With an affordable price under $100 and a universal fit requiring no tools to install, the Better Butts bidet can upgrade any bathroom in minutes.

The Better Butts bidet features an adjustable self-cleaning nozzle that provides a focused stream of fresh water for cleaning. The nozzle angle and water pressure are customizable for comfort, with settings retaining from use to use. When not needed, the nozzle tucks away into a protective housing.

“We created the Better Butts bidet to offer an easy way for people to improve their health and hygiene while also saving money and reducing their environmental impact,” said Brendan Brosnan, founder of Better Butts.

The Better Butts bidet is currently sold online through the company’s website and ships within 3-10 business days depending on location. International availability includes Canada, Mexico, and the UK.

To learn more about the Better Butts bidet, visit getbetterbutts.io or email support@betterbutts.co.

About Better Butts

Better Butts provides affordable, easy-to-install bidets to households and businesses focused on health, hygiene, and sustainability. Their non-electric bidets are designed to upgrade any standard toilet in minutes with no tools required.

Media Contact
Company Name: Better Butts
Email: Send Email
Country: United States
Website: http://www.getbetterbutts.io/

Bile Duct Neoplasm Market Forecast 2032: Analysis of Market Dynamics, Therapeutic Segmentation, Regional Insights, and Leading Players – Merck, AstraZeneca, Zymeworks, and More

“Bile Duct Neoplasm Market”

(New York, USA) DelveInsight’s “Bile Duct Neoplasm Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Bile Duct Neoplasm, historical and forecasted epidemiology as well as the Bile Duct Neoplasm market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Bile Duct Neoplasm market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Bile Duct Neoplasm market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Bile Duct Neoplasm treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Bile Duct Neoplasm market.

 

Request for a Free Sample Report @ Bile Duct Neoplasm Market Forecast

 

Some facts of the Bile Duct Neoplasm Market Report are:

  • According to DelveInsight, Bile Duct Neoplasm market size is expected to grow at a decent CAGR by 2032.
  • Leading Bile Duct Neoplasm companies working in the market are Merck, Incyte Corporation, AstraZeneca, Zymeworks, BeiGene, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences, Forma Therapeutics, Basilea Pharmaceutica, Celgene, Bristol Myer Squibb, Servier, and others.
  • Key Bile Duct Neoplasm Therapies expected to launch in the market are KEYTRUDA (pembrolizumab), Pemigatinib, IMFINZI (durvalumab), FUTIBATINIB (TAS-120), TASURGRATINIB (E7090), TT-00420, LENVIMA (lenvatinib), ZANIDATAMAB, Nab-paclitaxel, LONSURF (Trifluridine and Tipiracil Hydrochloride/TAS-102), FT-2102, Azacitidine and others.
  • According to the assessment done by DelveInsight, the estimated total Bile Duct Neoplasm diagnosed incident cases in the 7MM were approximately 46K in 2021.
  • On Feb 2023, Incyte Corporation announced a Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy – (FIGHT-202)
  • On Jan 2023, Forma Therapeutics announced a single agent, open-label study in up to five cohorts (glioma, hepatobiliary tumors, chondrosarcoma, intrahepatic cholangiocarcinoma, and other IDH1 mutant solid tumors) that will include a Phase 1 dose confirmation followed by a Phase 2 investigation of clinical activity in up to 4 cohorts. During the dose confirmation, additional doses or altered dose schedules may be explored.

 

Bile Duct Neoplasm Overview

Bile Duct Neoplasm, also known as cholangiocarcinoma, is a rare but aggressive form of cancer that originates in the bile ducts. These ducts are responsible for carrying bile, a fluid that aids in digestion, from the liver to the small intestine. Bile Duct Neoplasm can occur in different parts of the bile duct system, including the intrahepatic (inside the liver), perihilar (where the ducts join outside the liver), or distal (closer to the small intestine) regions. This type of cancer is challenging to diagnose in its early stages because symptoms may not appear until the disease has progressed. Common symptoms include jaundice (yellowing of the skin and eyes), abdominal pain, unexplained weight loss, and fatigue.

Risk factors for Bile Duct Neoplasm include chronic inflammation of the bile ducts, certain liver diseases, bile duct abnormalities, exposure to certain chemicals, and certain genetic conditions. However, the exact cause of most cases remains unknown.

Treatment options for Bile Duct Neoplasm include surgery, radiation therapy, chemotherapy, and targeted therapy. The choice of treatment depends on the stage and location of the cancer, as well as the overall health of the patient.

 

Learn more about Bile Duct Neoplasm treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/bile-duct-neoplasms-market

 

Bile Duct Neoplasm Market 

The Bile Duct Neoplasm market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Bile Duct Neoplasm market trends by analyzing the impact of current Bile Duct Neoplasm therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This section provides a comprehensive analysis of the Bile Duct Neoplasm market, focusing on the trends of each available drug and upcoming pipeline therapies. The evaluation includes factors such as the annual cost of therapy, criteria for inclusion and exclusion, mechanism of action, compliance rate, market demand, patient population growth, covered patient segment, expected launch year, competition with other therapies, brand value, and insights from key opinion leaders. The gathered data regarding the Bile Duct Neoplasm market is presented in easily understandable tables and graphs, offering a clear overview of the market.

According to DelveInsight, the Bile Duct Neoplasm market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Bile Duct Neoplasm Epidemiology

The Bile Duct Neoplasm epidemiology section provides insights into the historical and current Bile Duct Neoplasm patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Bile Duct Neoplasm market report also provides the diagnosed patient pool, trends, and assumptions.

 

Explore more about Bile Duct Neoplasm Epidemiology @ https://www.delveinsight.com/sample-request/bile-duct-neoplasms-market

 

Bile Duct Neoplasm Drugs Uptake

This section focuses on the uptake rate of the potential Bile Duct Neoplasm drugs recently launched in the Bile Duct Neoplasm market or expected to be launched in 2019-2032. The analysis covers the Bile Duct Neoplasm market uptake by drugs, patient uptake by therapies, and sales of each drug.

Bile Duct Neoplasm Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Bile Duct Neoplasm market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Bile Duct Neoplasm Pipeline Development Activities

  • KEYTRUDA (pembrolizumab): Merck Sharp & Dohme
  • IMFINZI (durvalumab): AstraZeneca
  • FUTIBATINIB (TAS-120): Taiho Oncology
  • TASURGRATINIB (E7090): Eisai
  • TT-00420: TransThera Sciences (Nanjing)
  • LENVIMA (lenvatinib): Eisai and Merck & Co
  • ZANIDATAMAB: Zymeworks and BeiGene
  • Nab-paclitaxel: Celgene/Bristol Myer Squibb
  • LONSURF (Trifluridine and Tipiracil Hydrochloride/TAS-102): Taiho Pharmaceutical/Servier

 

Request for a sample report to understand more about the Bile Duct Neoplasm pipeline development activities @ https://www.delveinsight.com/sample-request/bile-duct-neoplasms-market

 

Bile Duct Neoplasm Therapeutics Assessment

Major key companies are working proactively in the Bile Duct Neoplasm Therapeutics market to develop novel therapies which will drive the Bile Duct Neoplasm treatment markets in the upcoming years are Merck, AstraZeneca, Zymeworks, BeiGene, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences, Basilea Pharmaceutica, Celgene, Bristol Myer Squibb, Servier, and others.

 

Scope of Bile Duct Neoplasm Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
  • Base Year: 2021
  • Key Bile Duct Neoplasm Companies: Merck, AstraZeneca, Zymeworks, BeiGene, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences, Basilea Pharmaceutica, Celgene, Bristol Myer Squibb, Servier, and others.
  • Key Pipeline Bile Duct Neoplasm Therapies: KEYTRUDA (pembrolizumab), IMFINZI (durvalumab), FUTIBATINIB (TAS-120), TASURGRATINIB (E7090), TT-00420, LENVIMA (lenvatinib), ZANIDATAMAB, Nab-paclitaxel, LONSURF (Trifluridine and Tipiracil Hydrochloride/TAS-102), and others.

 

Learn more about the emerging Bile Duct Neoplasm therapies & key companies @ https://www.delveinsight.com/sample-request/bile-duct-neoplasms-market

 

Bile Duct Neoplasm Report Key Insights

1. Bile Duct Neoplasm Patient Population

2. Bile Duct Neoplasm Market Size and Trends

3. Key Cross Competition in the Bile Duct Neoplasm Market

4. Bile Duct Neoplasm Market Dynamics (Key Drivers and Barriers)

5. Bile Duct Neoplasm Market Opportunities

6. Bile Duct Neoplasm Therapeutic Approaches

7. Bile Duct Neoplasm Pipeline Analysis

8. Bile Duct Neoplasm Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Bile Duct Neoplasm Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Bile Duct Neoplasm Competitive Intelligence Analysis

4. Bile Duct Neoplasm Market Overview at a Glance

5. Bile Duct Neoplasm Disease Background and Overview

6. Bile Duct Neoplasm Patient Journey

7. Bile Duct Neoplasm Epidemiology and Patient Population

8. Bile Duct Neoplasm Treatment Algorithm, Current Treatment, and Medical Practices

9. Bile Duct Neoplasm Unmet Needs

10. Key Endpoints of Bile Duct Neoplasm Treatment

11. Bile Duct Neoplasm Marketed Products

12. Bile Duct Neoplasm Emerging Therapies

13. Bile Duct Neoplasm Seven Major Market Analysis

14. Attribute Analysis

15. Bile Duct Neoplasm Market Outlook (7 major markets)

16. Bile Duct Neoplasm Access and Reimbursement Overview

17. KOL Views on the Bile Duct Neoplasm Market

18. Bile Duct Neoplasm Market Drivers

19. Bile Duct Neoplasm Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bile Duct Neoplasm Market Forecast 2032: Analysis of Market Dynamics, Therapeutic Segmentation, Regional Insights, and Leading Players – Merck, AstraZeneca, Zymeworks, and More

Inherited Retinal Diseases Market to witness growth by 2032, estimates DelveInsight | GenSight Biologics, Endogena Therapeutics, Aldeyra Therapeutics, Nanoscope Therapeutics, ProQR Therapeutics

“Inherited Retinal Diseases Market”

(Albany, USA) DelveInsight’s “Inherited Retinal Diseases Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Inherited Retinal Diseases, historical and forecasted epidemiology as well as the Inherited Retinal Diseases market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Inherited Retinal Diseases market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Inherited Retinal Diseases market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Inherited Retinal Diseases treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Inherited Retinal Diseases market.

 

Request for a Free Sample Report @ Inherited Retinal Diseases Market Forecast

 

Some facts of the Inherited Retinal Diseases Market Report are:

  • According to DelveInsight, Inherited Retinal Diseases market size is expected to grow at a decent CAGR by 2032.
  • Leading Inherited Retinal Diseases companies working in the market are GenSight Biologics, Endogena Therapeutics, Aldeyra Therapeutics, Nanoscope Therapeutics, ProQR Therapeutics, and others.
  • Key Inherited Retinal Diseases Therapies expected to launch in the market are EA-2353, ADX-2191, GS030-DP, MCO-010, and others.
  • As per NORD, vision disorders affects about 1 in 3,000 to 1 in 4,000 people in the world. This shows that about 82,500 to 110,000 people that is in the United States have RP or a related disorder. The prevalence of choroideremia is estimated to be approximately 1:50,000 in people of European descent (Zinkernagel & MacLaren, 2015).
  • The National Institute of Health and Research UK (n.d.) estimates that RP affects 1 in 4000 people in the United Kingdom.

 

Inherited Retinal Diseases Overview

Inherited retinal diseases (IRDs) are a clinically and genetically heterogeneous group of disorders characterized by photoreceptor degeneration or dysfunction. These disorders typically present with severe vision loss that can be progressive, with disease onset ranging from congenital to late adulthood.

IRDs are caused by a change or ‘mistake’ in one or more genes. Therefore, cells in the retina don’t work as they are supposed to and over time you lose vision. Currently there are around 250 genes known to cause IRD. There are many more genes, but they haven’t been discovered yet.

Some common symptoms of inherited retinal diseases include finding it hard to see in dim or dark settings, reduced side vision – bumping into objects or people, glare and difficulty in bright light and many more.

 

Learn more about Inherited Retinal Diseases treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/inherited-retinal-disease-market

 

Inherited Retinal Diseases Market 

The Inherited Retinal Diseases market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Inherited Retinal Diseases market trends by analyzing the impact of current Inherited Retinal Diseases therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Inherited Retinal Diseases market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Inherited Retinal Diseases market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Inherited Retinal Diseases market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Inherited Retinal Diseases Epidemiology 

The Inherited Retinal Diseases epidemiology section provides insights into the historical and current Inherited Retinal Diseases patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Inherited Retinal Diseases market report also provides the diagnosed patient pool, trends, and assumptions. 

 

Explore more about Inherited Retinal Diseases Epidemiology @ Inherited Retinal Diseases Market Dynamics

 

Inherited Retinal Diseases Drugs Uptake

This section focuses on the uptake rate of the potential Inherited Retinal Diseases drugs recently launched in the Inherited Retinal Diseases market or expected to be launched in 2019-2032. The analysis covers the Inherited Retinal Diseases market uptake by drugs, patient uptake by therapies, and sales of each drug.

Inherited Retinal Diseases Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Inherited Retinal Diseases market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Inherited Retinal Diseases Pipeline Development Activities

The Inherited Retinal Diseases report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Inherited Retinal Diseases key players involved in developing targeted therapeutics.

 

Request for a sample report to understand more about the Inherited Retinal Diseases pipeline development activities @ https://www.delveinsight.com/sample-request/inherited-retinal-disease-market

 

Inherited Retinal Diseases Therapeutics Assessment

Major key companies are working proactively in the Inherited Retinal Diseases Therapeutics market to develop novel therapies which will drive the Inherited Retinal Diseases treatment markets in the upcoming years are GenSight Biologics, Endogena Therapeutics, Aldeyra Therapeutics, Nanoscope Therapeutics, ProQR Therapeutics, and others.

 

Learn more about the emerging Inherited Retinal Diseases therapies & key companies @ https://www.delveinsight.com/sample-request/inherited-retinal-disease-market

 

Inherited Retinal Diseases Report Key Insights

1. Inherited Retinal Diseases Patient Population

2. Inherited Retinal Diseases Market Size and Trends

3. Key Cross Competition in the Inherited Retinal Diseases Market

4. Inherited Retinal Diseases Market Dynamics (Key Drivers and Barriers)

5. Inherited Retinal Diseases Market Opportunities

6. Inherited Retinal Diseases Therapeutic Approaches

7. Inherited Retinal Diseases Pipeline Analysis

8. Inherited Retinal Diseases Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Inherited Retinal Diseases Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Inherited Retinal Diseases Competitive Intelligence Analysis

4. Inherited Retinal Diseases Market Overview at a Glance

5. Inherited Retinal Diseases Disease Background and Overview

6. Inherited Retinal Diseases Patient Journey

7. Inherited Retinal Diseases Epidemiology and Patient Population

8. Inherited Retinal Diseases Treatment Algorithm, Current Treatment, and Medical Practices

9. Inherited Retinal Diseases Unmet Needs

10. Key Endpoints of Inherited Retinal Diseases Treatment

11. Inherited Retinal Diseases Marketed Products

12. Inherited Retinal Diseases Emerging Therapies

13. Inherited Retinal Diseases Seven Major Market Analysis

14. Attribute Analysis

15. Inherited Retinal Diseases Market Outlook (7 major markets)

16. Inherited Retinal Diseases Access and Reimbursement Overview

17. KOL Views on the Inherited Retinal Diseases Market

18. Inherited Retinal Diseases Market Drivers

19. Inherited Retinal Diseases Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Inherited Retinal Diseases Market to witness growth by 2032, estimates DelveInsight | GenSight Biologics, Endogena Therapeutics, Aldeyra Therapeutics, Nanoscope Therapeutics, ProQR Therapeutics

Supersox, a brand by Super Knit Industries, is here to make people rethink what’s on their feet

Supersox, a brand by Super Knit Industries, is here to make people rethink what's on their feet
This brand is elevating sock excellence in India and beyond.

Super Knit Industries (SKI), a name synonymous with sock manufacturing excellence for over two decades, proudly presents its flagship brand, Supersox. This venture, led by the dynamic second-generation entrepreneurs, Harsh Saraf and Vivek Saraf, is redefining the sock industry in India and beyond. SKI is India’s largest socks manufacturer having the highest number of global certifications like WRAP, CTPAT, SA8000, Sedex, GOTS, GRS, Disney FAMA, Oeko-Tex Class 1, ISO 9001, 14001, 45001, BCI, PCC etc. They have won more than 30 awards, ‘Most Innovative Company of the Year 2023’ by Prime Insights being the most recent one.

Established in 2012, Supersox builds upon the legacy and reputation of Super Knit Industries (SKI), which has been a leading exporter of high-quality cotton socks to global markets since 1999. They have a vision to cover every foot in the world with their socks. They were featured by Google as the best socks brand in the world.

“Supersox is more than just a sock brand; it’s a commitment to quality, comfort, durability, feel-good factor, and sustainability. We’re on a mission to close the gap between everyday socks and exceptional comfort for our customers,” says Harsh Saraf, co-founder of Supersox.

Supersox offers a diverse range of socks for men, women, kids, and babies, made from the finest materials, ensuring unmatched comfort, breathability, and durability. With a rich history, over 8,000 SKUs, and 1,00,000 designs, Supersox is committed to quality and innovation, recent examples being Bamboo socks, Football socks, Modal socks. Its collaborations with brands like Disney Frozen, Princess, Mickey & Friends, Minnie & Marvel, Avengers, and more make Supersox a true fashion statement.

As Supersox continues to grow and make its mark, the website, www.supersox.com, will serve as the one stop shop for all things Supersox. Moreover, Supersox products are available on all major Indian e-commerce platforms, including Amazon India, Flipkart, and Myntra, making it super accessible for customers to find the best cotton socks for every occasion.

Super Knit Industries, with its 20+ years of experience, over 15 million annual production capacity, and 40,000+ sq. ft. factory area, has been achieving several milestones for the Indian sock industry with Supersox. Choose Supersox – socks that look good and feel even better!

About Super Knit Industries

Super Knit Industries, a pioneering force in sock manufacturing for over two decades, has unveiled Supersox, its flagship brand. Established in 2012, Supersox, led by second-generation entrepreneurs Harsh Saraf and Vivek Saraf, is dedicated to delivering top-quality, innovative, and sustainable socks to individuals of all ages in India and across the world. With a rich legacy and an impressive range of products, Supersox aims to redefine the sock industry, offering unparalleled comfort and style.

Media Contact
Company Name: Super Knit Industries
Contact Person: SKI Support
Email: Send Email
Country: India
Website: https://superknit.com/

NAKED body essentials: Redefining Skincare through All-Natural Ingredients

NAKED body essentials: Redefining Skincare through All-Natural Ingredients
Award-winning luxury skincare line continues to single-handedly revolutionize family skincare.

NAKED body essentials, a distinguished beauty and wellness brand, is reshaping the skincare industry with its unwavering commitment to all-natural, family centric skincare solutions that harness the remarkable healing properties of nature.

Recent years have seen a shift towards clean beauty, with consumers increasingly prioritizing products formulated with natural non-toxic ingredients. NAKED body essentials award-winning offerings reflect this growing consumer demand, focusing on solutions that not only redefine the pursuit of radiant, healthy skin but align with ethical and sustainable practices.

Imagine skincare that caters to the unique needs of every family member. NAKED body essentials offers comprehensive solutions for an extensive range of skin conditions, including acne, rosacea, eczema, fine lines, and wrinkles. Free from harsh chemicals, they provide deep hydration, soothing relief, and gentle cleansing. What sets NAKED body essentials apart is the multifaceted benefits that go far beyond surface level results. With a holistic approach to wellness rarely seen in skincare, NAKED body essentials connects on a deeper level with its Wellness Collection. A product line that provides benefits such as promoting improved sleep, as well as aiding in the alleviation of migraine and PMS symptoms.

At the core of NAKED body essentials’ philosophy lies a deep belief in the power of nature’s gifts. By skillfully blending botanical extracts, essential oils, and cutting edge innovation each product is meticulously handcrafted to rejuvenate your skin and ignite a newfound vitality. Creating a cleaner healthier lifestyle for you and your loved ones while nurturing your body and mind.

NAKED body essentials dedication to handcrafted luxury and efficacy echoes through the numerous testimonials that speak volumes about its impact. Satisfied customers who have witnessed remarkable transformations in their skin conditions and overall well-being, endorsing the brand’s unwavering commitment to authenticity, effectiveness, and quality.

Moreover, NAKED body essentials remains committed to continuous innovation, ensuring its offerings align with the evolving needs of its audience, and enriching customer experiences. By advocating for clean, thoughtfully sourced ingredients and holistic health, NAKED body essentials drives a movement toward a more conscientious approach to skincare.

With a remarkable range of all-natural skincare products and a relentless pursuit of excellence, NAKED body essentials stands at the forefront of its industry, revolutionizing family skincare and promoting a renewed sense of excitement and well-being.

To discover more about NAKED body essentials and experience the transformative power of each of their products, visit https://loveNAKEDskin.com.

About NAKED body essentials

NAKED body essentials is a family owned skincare brand committed to delivering all natural, handcrafted skincare solutions. Aiming to redefine the skincare and beauty landscape by emphasizing clean, conscientiously sourced ingredients. Its diverse offerings address a wide array of skin concerns, leaving the skin nourished and rejuvenated. Beyond products, NAKED body essentials fosters a supportive community of mindful and empowered shoppers.

Media Contact
Company Name: NAKED Skin Inc | NAKED body essentials
Contact Person: Media Relations
Email: Send Email
Phone: 866-816-2626
Country: United States
Website: https://loveNAKEDskin.com

Media Streaming Market Revenues to Reach USD 173.73 Billion by 2028 – Market Size, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence

According to the latest research report titled, “Media Streaming Market Report (2023 – 2028)” by Mordor Intelligence, the market is estimated at USD 119.01 billion in 2023 and growing at a CAGR of 7.86% during the forecast period. 

The enhancement of media quality is propelled by innovations such as blockchain technology and artificial intelligence (AI). AI contributes significantly to various aspects of video creation and uploading, including editing, cinematography, voice-overs, and scriptwriting. Numerous providers of media streaming solutions are utilizing AI to enhance content quality, leading to a surge in popularity for these platforms over traditional media outlets like YouTube and Netflix. 

The media streaming market is experiencing growth propelled by a rising demand for subscription-based services, the expanding availability of region-specific and original content, and the widespread popularity of live sports. These factors are prompting vendors in the market to adjust their strategies, placing a greater emphasis on enhancing customer experience through personalized offerings and cost-effective services daily. 

According to a report titled “India Embraces the Streaming Era,” released today by Magnite, the world’s largest independent omnichannel sell-side advertising platform, findings reveal that advertisements on streaming platforms garner greater attention compared to those on social media. Nearly two-thirds of Indian streamers (64%) exhibit higher receptivity to advertising on streaming platforms, with a significant number indicating their tendency to conduct product searches (48%) and make purchases (33%) after exposure. 

 Report Summary 

  • Market Size (2023): USD 119.01 Billion 
  • Market Size (2028): USD 173.73 Billion 
  • CAGR (2023 – 2028): 7.86% 
  • Study Period: (2018-2028) 
  • Fastest Growing Market: Asia-Pacific  
  • Fastest Growing Market: North America  
  • Forecast Units: Value (USD Billion) 
  • Report Scope: Market Dynamics, Revenue Forecast & Segmentation, Competitive Landscape & Recent Developments, Market Growth, Future Opportunities, and Trends 
  • Key Market Drivers: Easy Accessibility and Playlist Customization on Various Audio Streaming Platforms, Growing Adoption of Subscription Video on-demand (SVoD) Services and Increasing Popularity of Live Sports Streaming Services  

Which are the Top Companies in the Media Streaming Market?     

The media streaming industry exhibits significant fragmentation due to the presence of major players and increasing competition. Market vendors are focused on offering valuable bundles, introducing innovative features, and delivering high-quality, original, and region-specific content to gain a competitive edge and enhance their market standing through customer acquisition. 

In November 2022, a new multi-year distribution arrangement was announced between Paramount and Virgin Media, extending their long-standing collaboration across all of Paramount’s linear channels and streaming platforms in the UK.  

Prominent players in the media streaming market are: 

  • Spotify Technology S.A. 
  • Apple Inc. 
  • Amazon Prime (Amazon.com Inc.) 
  • Tencent Holdings Limited 
  • Deezer SA 
  • YouTube (Alphabet Inc.) 
  • AT&T Inc. 
  • Pandora Media Inc. 
  • The Walt Disney Company 
  • Baidu Inc. 
  • British Broadcasting Corporation 

Other Reports that Might be of Your Interest 

  • Video-on-Demand Market Report: The Video-on-Demand Market size is estimated at USD 104.42 billion in 2023, and is expected to reach USD 173.27 billion by 2028, growing at a CAGR of 10.66% during the forecast period (2023-2028). 
  • Music Publishing Market Report: The Music Publishing Market size is expected to grow from USD 6.86 billion in 2023 to USD 9.12 billion by 2028, at a CAGR of 5.87% during the forecast period (2023-2028). 

 

Key Highlights from the Media Streaming Market Report 

 

1. Substantial Growth is Anticipated in The Music Streaming Segment 

  • Music streaming platforms leverage exclusive content, podcasts, and original material to attract users, converting them into subscribers 
  • Promotional activities, such as price cuts and bundled offers in emerging markets, contribute to subscriber base expansion 
  • Spotify’s success, with a 31% YoY revenue growth and a 35% share of paid subscriptions, can be attributed to strategic promotions like free premium subscriptions and subscription model discounts 
  • The global market witnessed a notable trend in the adoption of 5G connections, enhancing music streaming experiences 
  • Amazon is capitalizing on 5G by introducing a music HD service in select countries, offering lossless music streams and downloads 
  • The increasing prevalence of 5G enables businesses to deliver high-fidelity music streams at significantly faster data transmission rates than 4G 
  • Virtual Reality (VR), Augmented Reality (AR), and hologram concerts are anticipated to gain popularity in live-streaming music videos 
  • Companies emphasize customer retention through engaging features, as reflected in the creation of 82,000 New Year’s Eve playlists between December and January 
  • The dynamic playlist creation, with almost 40,000 playlists made on New Year’s Eve itself, illustrates the evolving market landscape and consumer preferences  

2. Asia Pacific to Witness Significant Growth  

As per the IFPI Music Report 2022, “Engaging with Music 2022” is a global study on how individuals worldwide enjoy and interact with music. Published by IFPI, the global representative of the recording industry, this survey, comprising responses from over 44,000 participants across 22 countries, marks the most extensive music study ever conducted. Notably, more than 45% of consumers opt for paid membership services, while 46% use audio-streaming subscription services, granting them uninterrupted access to extensive libraries of licensed songs. 

Additionally, the report highlights that 97% of the global population prefers smartphones for music listening, with 62% utilizing social media platforms or apps to enjoy music or watch music videos. These findings underscore the ongoing shift towards digital media consumption globally, further indicating the prospective growth of the media streaming market. 

What are the Latest Developments in the Media Streaming Market?    

  • In January 2023: IndiaCast Media Distribution Pvt. Ltd., the multi-platform content asset monetization entity jointly owned by TV18 and Viacom18, partnered with Amagi to launch Desi Play TV, a free ad-supported streaming television (FAST) channel in HD on Sling in the US and Plex across the US, Canada, and Middle East regions. Amagi is a world leader in cloud-based SaaS technology for broadcast and connected TV. 
  • In January 2023: To handle the increase in local and international demand for the 2022 FIFA World Cup, Beyond Technology, a global player in technology transformation, and Infinera successfully implemented a 3.6 Terabit network for a top Middle Eastern network operator. 

Mordor Intelligence Report on the Media Streaming Market segments the market based on product type, application, and geography: 

  • By Content Type (Market Size & Forecast based on Value (USD Billion), 2023-2028)   
  • Music streaming 
  • Video Streaming 
  • By Revenue Model (Market Size & Forecast based on Value (USD Billion), 2023-2028)   
  • Advertising  
  • Subscription  
  • By Streaming Platform (Market Size & Forecast based on Value (USD Billion), 2023-2028)   
  • Smartphone & Tablet 
  • Laptop and Desktop 
  • Smart TV 
  • Gaming Console 
  • By Geography (Market Size & Forecast based on Value (USD Billion), 2023-2028)   
  • North America 
  • United States 
  • Canada 
  • Europe 
  • Germany 
  • United Kingdom 
  • France 
  • Spain 
  • Rest of Europe 
  • Asia-Pacific 
  • China 
  • Japan 
  • India 
  • Australia 
  • Rest of Asia-Pacific 
  • Latin America 
  • Brazil 
  • Mexico 
  • Argentina 
  • Rest of Latin America 
  • Middle East and Africa 
  • UAE 
  • Saudi Arabia 
  • South Africa 
  • Rest of Middle East and Africa  

In a nutshell, the Mordor Intelligence Market Research Report provides in-depth market insight to industry players, investors, researchers, consultants, and business strategists, looking for comprehensive details on the media streaming market industry. Get a glance at the Media Streaming Market Report (2023 – 2028) 

About Mordor Intelligence 

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.  

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.   

Other Related Reports that Might be of Interest 

  • Video Encoder Market Report: The Video Encoder Market size is expected to grow from USD 2.33 billion in 2023 to USD 2.92 billion by 2028, at a CAGR of 4.60% during the forecast period (2023-2028).  
  • India Smart TV and OTT Market Report: The India Smart TV and OTT Market size is expected to grow from USD 16.02 billion in 2023 to USD 36.97 billion by 2028, at a CAGR of 18.20% during the forecast period (2023-2028). 

Media Contact
Company Name: Mordor Intelligence Private Limited
Contact Person: Prateeksha Rawat
Email: Send Email
Phone: +1 617-765-2493
Address:5th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli
City: Hyderabad
State: Telangana 500008
Country: India
Website: https://www.mordorintelligence.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Media Streaming Market Revenues to Reach USD 173.73 Billion by 2028 – Market Size, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence

Essentials Hoodies Illuminates The Artistic Vision With A New Year Collection

The merch allows fans to shine a light on the enduring style that has the world taking notice thanks to its fashion flair and visionary design.

Essentials Hoodies, an online store renowned for its timeless style and quality, has announced the launch of a groundbreaking New Year collection. With an unwavering commitment to embody the vision of the brand’s founder, Jerry Lorenzo, the collection aims to kickstart the new year with style and offer fans a chance to embrace the iconic and enduring allure of Essentials Hoodies.

In a statement to the press, a senior spokesperson for Essentials Hoodies said, “We are very excited to unveil this trendsetting New Year collection that is a celebration of fashion diversity that not only reflects the unique styles of the fans but also pays homage to Jerry Lorenzo’s visionary approach. We want to be a torchbearer for Jerry Lorenzo’s Vision of timeless pieces that transcend fleeting trends. We hope fans will appreciate our brand’s dedication to quality and enduring style.”

They worked with world class designers to craft each item so that it embodies the spirit of Essentials Hoodies and brings joy and a touch of sophistication to fans across the globe. The New Year collection from Essentials Hoodies features diverse items, showcasing the brand’s commitment to offering timeless pieces that cut across changing fashion trends without people having to break the bank. The items that symbolize their love for the brand and allow them to embrace its Vision of high-quality and enduring fashion.

He went on to add, “This collection is our tribute to the passionate community that has embraced Essentials Hoodies as a global fashion sensation. We aim to provide fans with merchandise that mirrors the essence of Jerry Lorenzo’s Vision and allows them to carry a piece of this visionary approach into the promising months ahead. Our goal is to offer fans unique items that showcase their allegiance and set the tone for a chic and confident new year.”

To enhance the New Year shopping experience, Essentials Hoodies offers fast shipping to countries across the globe and an enticing 15% discount on purchases exceeding $100. Fans eager to explore the New Year collection and infuse their wardrobes with Essentials Hoodies’ iconic style can visit the website Essentials-hoodies.com today.

Media Contact
Company Name: Essentials Hoodies
Contact Person: Kakie Tong
Email: Send Email
Address:111 Samuel’s Lane
City: Selden
State: NY 11784
Country: United States
Website: https://essentials-hoodies.com/